$256 Million is the total value of Rhenman & Partners Asset Management AB's 84 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| REGN | New | Regeneron Pharmaceuticals Inc | $10,184,000 | – | 37,000 | +100.0% | 3.98% | – |
| CELG | New | Celgene Corp | $8,279,000 | – | 49,000 | +100.0% | 3.24% | – |
| GILD | New | Gilead Sciences Inc | $8,191,000 | – | 109,000 | +100.0% | 3.20% | – |
| CVS | New | CVS Caremark Corp | $7,658,000 | – | 107,000 | +100.0% | 3.00% | – |
| BIIB | New | Biogen IDEC Inc | $7,553,000 | – | 27,000 | +100.0% | 2.95% | – |
| P103PS | New | NPS Pharmaceuticals Inc | $7,286,000 | – | 240,000 | +100.0% | 2.85% | – |
| BMRN | New | BioMarin Pharmaceutical Inc | $7,027,000 | – | 100,000 | +100.0% | 2.75% | – |
| ALXN | New | Alexion Pharmaceuticals Inc | $6,653,000 | – | 50,000 | +100.0% | 2.60% | – |
| PCYC | New | Pharmacyclics Inc | $6,347,000 | – | 60,000 | +100.0% | 2.48% | – |
| ALKS | New | Alkermes Plc | $5,896,000 | – | 145,000 | +100.0% | 2.31% | – |
| AEGR | New | Aegerion Pharmaceuticals Inc | $5,322,000 | – | 75,000 | +100.0% | 2.08% | – |
| KERX | New | Keryx Biopharmaceuticals Inc | $5,180,000 | – | 400,000 | +100.0% | 2.03% | – |
| SLXP | New | Salix Pharmaceutical Ltd | $4,947,000 | – | 55,000 | +100.0% | 1.94% | – |
| ARIA | New | Ariad Pharmaceuticals Inc | $4,774,000 | – | 700,000 | +100.0% | 1.87% | – |
| THRX | New | Theravance Inc | $4,706,000 | – | 132,000 | +100.0% | 1.84% | – |
| JNJ | New | Johnson & Johnsoncall | $4,580,000 | – | 50,000 | +100.0% | 1.79% | – |
| ESRX | New | Express Scripts Hg Co | $4,566,000 | – | 65,000 | +100.0% | 1.79% | – |
| INCY | New | Incyte Corp Ltd | $4,304,000 | – | 85,000 | +100.0% | 1.68% | – |
| MDT | New | Medtronic Inc | $4,304,000 | – | 75,000 | +100.0% | 1.68% | – |
| MRK | New | Merck Co Inc | $4,254,000 | – | 85,000 | +100.0% | 1.66% | – |
| BMY | New | Bristol Myers Squibb Co | $3,827,000 | – | 72,000 | +100.0% | 1.50% | – |
| UNH | New | United Health Group Inc | $3,313,000 | – | 44,000 | +100.0% | 1.30% | – |
| BSX | New | Boston Scientific Corp | $3,306,000 | – | 275,000 | +100.0% | 1.29% | – |
| FRX | New | Forest Laboratories Inc | $3,302,000 | – | 55,000 | +100.0% | 1.29% | – |
| ISRG | New | Intuitive Surgical Inc | $3,073,000 | – | 8,000 | +100.0% | 1.20% | – |
| F113PS | New | Covidien Plc | $3,065,000 | – | 45,000 | +100.0% | 1.20% | – |
| V107SC | New | WellPoint Inc | $2,956,000 | – | 32,000 | +100.0% | 1.16% | – |
| INFI | New | Infinity Pharm Inc | $2,900,000 | – | 210,000 | +100.0% | 1.13% | – |
| ABC | New | AmerisourceBergen Corp | $2,812,000 | – | 40,000 | +100.0% | 1.10% | – |
| ZBH | New | Zimmer Holdings Inc | $2,796,000 | – | 30,000 | +100.0% | 1.09% | – |
| PODD | New | Insulet Corp | $2,783,000 | – | 75,000 | +100.0% | 1.09% | – |
| TMO | New | Thermo Fisher Scientific Inc | $2,784,000 | – | 25,000 | +100.0% | 1.09% | – |
| AGN | New | Allergan Inc | $2,777,000 | – | 25,000 | +100.0% | 1.09% | – |
| BDX | New | Becton Dickinson & Co | $2,762,000 | – | 25,000 | +100.0% | 1.08% | – |
| JNJ | New | Johnson & Johnson | $2,748,000 | – | 30,000 | +100.0% | 1.08% | – |
| THOR | New | Thoratec Corp | $2,745,000 | – | 75,000 | +100.0% | 1.07% | – |
| AET | New | Aetna Inc | $2,744,000 | – | 40,000 | +100.0% | 1.07% | – |
| DVAX | New | Dynavax Technologies Corp | $2,744,000 | – | 1,400,000 | +100.0% | 1.07% | – |
| DXCM | New | Dexcom Inc | $2,727,000 | – | 77,000 | +100.0% | 1.07% | – |
| VAR | New | Varian Medical Systems Inc | $2,719,000 | – | 35,000 | +100.0% | 1.06% | – |
| HCA | New | HCA Holdings Inc | $2,624,000 | – | 55,000 | +100.0% | 1.03% | – |
| PRXL | New | Parexel Intl Corp | $2,620,000 | – | 58,000 | +100.0% | 1.02% | – |
| CYBX | New | Cyberonics Inc | $2,620,000 | – | 40,000 | +100.0% | 1.02% | – |
| TEVA | New | Teva Pharma Ind Ltdadr | $2,605,000 | – | 65,000 | +100.0% | 1.02% | – |
| BAX | New | Baxter Intl Inc | $2,573,000 | – | 37,000 | +100.0% | 1.01% | – |
| STJ | New | St Jude Medical Inc | $2,478,000 | – | 40,000 | +100.0% | 0.97% | – |
| CI | New | Cigna Corp | $2,362,000 | – | 27,000 | +100.0% | 0.92% | – |
| A | New | Agilent Technologies Inc | $2,288,000 | – | 40,000 | +100.0% | 0.90% | – |
| OCR | New | Omnicare Inc | $2,233,000 | – | 37,000 | +100.0% | 0.87% | – |
| HPTX | New | Hyperion Therapeutics Inc | $2,224,000 | – | 110,000 | +100.0% | 0.87% | – |
| CLDX | New | Celldex Therapeutics Inc | $2,179,000 | – | 90,000 | +100.0% | 0.85% | – |
| NKTR | New | Nektar Therapeutics | $2,157,000 | – | 190,000 | +100.0% | 0.84% | – |
| IART | New | Integra Lifesciences Hgs Corp | $2,147,000 | – | 45,000 | +100.0% | 0.84% | – |
| EXEL | New | Exelixis Inc | $2,146,000 | – | 350,000 | +100.0% | 0.84% | – |
| ACAD | New | Acadia Pharmaceuticals Inc | $2,124,000 | – | 85,000 | +100.0% | 0.83% | – |
| MCK | New | McKesson Corp | $2,098,000 | – | 13,000 | +100.0% | 0.82% | – |
| CNC | New | Centene Corp | $2,063,000 | – | 35,000 | +100.0% | 0.81% | – |
| LGND | New | Ligand Pharmaceuticals Inc | $1,999,000 | – | 38,000 | +100.0% | 0.78% | – |
| PKI | New | Perkin Elmer Inc | $1,855,000 | – | 45,000 | +100.0% | 0.73% | – |
| ARRY | New | Array BioPharma Inc | $1,804,000 | – | 360,000 | +100.0% | 0.71% | – |
| LLY | New | Eli Lilly & Co | $1,785,000 | – | 35,000 | +100.0% | 0.70% | – |
| CYH | New | Community Health Syst Inc | $1,767,000 | – | 45,000 | +100.0% | 0.69% | – |
| AUXL | New | Auxilium Pharmaceuticals Inc | $1,763,000 | – | 85,000 | +100.0% | 0.69% | – |
| BCR | New | CR Bard Inc | $1,741,000 | – | 13,000 | +100.0% | 0.68% | – |
| ABMD | New | Abiomed Inc | $1,738,000 | – | 65,000 | +100.0% | 0.68% | – |
| SUPN | New | Supernus Pharmaceuticals Inc | $1,697,000 | – | 225,000 | +100.0% | 0.66% | – |
| MYGN | New | Myriad Genetics Inc | $1,694,000 | – | 80,759 | +100.0% | 0.66% | – |
| B108PS | New | Actavis Plc | $1,680,000 | – | 10,000 | +100.0% | 0.66% | – |
| HOLX | New | Hologic Inc | $1,609,000 | – | 72,000 | +100.0% | 0.63% | – |
| IMGN | New | ImmunoGen Inc | $1,467,000 | – | 100,000 | +100.0% | 0.57% | – |
| ELGX | New | Endologix Inc | $1,413,000 | – | 81,027 | +100.0% | 0.55% | – |
| OREX | New | Orexigen Therapeutics Inc | $1,408,000 | – | 250,000 | +100.0% | 0.55% | – |
| CPHD | New | Cepheid Inc | $1,402,000 | – | 30,000 | +100.0% | 0.55% | – |
| HAE | New | Haemonetics Corp | $1,264,000 | – | 30,000 | +100.0% | 0.49% | – |
| THLD | New | Threshold Pharmaceuticals | $1,168,000 | – | 250,000 | +100.0% | 0.46% | – |
| TROV | New | TrovaGene Inc | $1,148,000 | – | 200,000 | +100.0% | 0.45% | – |
| 5100PS | New | Volcano Corp | $983,000 | – | 45,000 | +100.0% | 0.38% | – |
| NLNK | New | NewLink Genetics Corp | $880,000 | – | 40,000 | +100.0% | 0.34% | – |
| MDRX | New | Allscripts Healthcare So Inc | $850,000 | – | 55,000 | +100.0% | 0.33% | – |
| LXRX | New | Lexicon Pharmaceuticals Inc | $540,000 | – | 300,000 | +100.0% | 0.21% | – |
| SNTA | New | Synta Pharmaceuticals Corp | $524,000 | – | 100,000 | +100.0% | 0.20% | – |
| NVDQ | New | Novadaq Technologies Inc | $412,000 | – | 25,000 | +100.0% | 0.16% | – |
| ANTH | New | Anthera Pharmaceuticals Inc | $366,000 | – | 119,297 | +100.0% | 0.14% | – |
| ECYT | New | Endocyte Inc | $267,000 | – | 25,000 | +100.0% | 0.10% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITEDHEALTH GROUP INC | 40 | Q3 2023 | 4.0% |
| BIOMARIN PHARMACEUTICAL INC | 40 | Q3 2023 | 5.0% |
| ALKERMES PLC | 40 | Q3 2023 | 3.3% |
| LILLY ELI & CO | 39 | Q3 2023 | 5.8% |
| CVS HEALTH CORP | 39 | Q3 2023 | 3.5% |
| INTRA-CELLULAR THERAPIES INC | 39 | Q3 2023 | 2.4% |
| EDWARDS LIFESCIENCES CORP | 39 | Q3 2023 | 1.7% |
| VERTEX PHARMACEUTICALS INC | 38 | Q3 2023 | 4.3% |
| REVANCE THERAPEUTICS INC | 38 | Q3 2023 | 0.9% |
| ABBVIE INC | 37 | Q3 2023 | 4.4% |
View Rhenman & Partners Asset Management AB's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-13 |
| 13F-HR/A | 2023-11-13 |
| 13F-HR | 2023-11-09 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-11 |
View Rhenman & Partners Asset Management AB's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.